



# Impact by the Numbers

## 2021

Explore the impact we've made on patients,  
science and communities

People. Passion.  
Possibilities.®

**AbbVie** is a research-driven biopharmaceutical company that takes on the toughest health challenges. But we do more than treat diseases—we embrace the responsibility of making a remarkable impact on people’s lives through the innovative medicines and solutions we create together. This is driven by our compassion for people, commitment to innovation and inclusion, service to the community and uncompromising integrity.

At AbbVie, we care deeply for patients, customers and their caregivers, our employees and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety and performance. We invest and innovate relentlessly to tackle unmet needs, creating new medicines and health care approaches for a healthier world.

We proudly do our part, serving and supporting our communities and protecting the environment so we can make a lasting impact on health care and beyond.

**Therapeutic areas of focus:**

- Immunology
- Oncology
- Neuroscience
- Eye Care
- Virology
- Aesthetics

Globally, our employees represent diverse backgrounds and perspectives, and our company values treating everyone with dignity and respect—which we believe allows us to achieve our best.

**~50K**

employees turning possibilities into reality for people and patients

**60+**

conditions treated across all stages of life

**220+**

research partnerships

**175+**

countries where products help people and patients

**~20**

countries with manufacturing and/or R&D facilities

Our focus on people and culture, serving our communities and operating with integrity, continues to be recognized by others.



**Workplace & Diversity**

DiversityInc. “Top 50 Companies for Diversity” – Top 15

FORTUNE “100 Best Companies to Work For” – Included for four consecutive years

Great Place to Work “World’s Best Workplaces” – Included for five consecutive years

Human Rights Campaign Corporate Equality Index – Scored 100% for six consecutive years

Seramount “100 Best Companies”



**Citizenship**

Civic 50

3BL Media “100 Best Corporate Citizens”

PEOPLE Companies That Care

Bioethics International Good Pharma Scorecard for clinical trial transparency – Tied for first



**Business Performance**

FORTUNE 100

FORTUNE World’s Most Admired Companies



**Environment, Social and Governance**

Dow Jones Sustainability World Index

Dow Jones Sustainability North America Index

EcoVadis Corporate Social Responsibility Assessment Gold Medal

FTSE4Good Index

S&P 500 ESG Index

AbbVie ranked on the 2021 Purpose Power Index

# Impact on patients

We put patients at the center of everything we do

We empathize with and work to understand the experiences of people living with conditions so that we can meet their specialized needs.

**“At the time I was diagnosed, the options weren’t really great options. Because of the options I have now, I have a completely different outlook.”**

**Ben**  
Patient with chronic lymphocytic leukemia



**~62M+**

people are treated by AbbVie’s products every year including more than 18 million people in the United States

**1.6B+**

people have the potential to be treated by therapies we are researching, including nearly 280 million people in the United States

**175+**

countries where our products help people and patients

**10**

new therapies and indications received regulatory approval in 2021 in neuroscience, eye care and immunology focus areas

## Proactively supporting patients through AbbVie programs

**550+**

patient support programs globally

**180+**

patient support programs in the United States

### Access to medicine

Innovative treatments can only make a difference if patients can access the medicines that they and their providers choose. Innovation and access must work in tandem, which is why we’re committed to helping eligible patients get the medicines they need.

**170K+**

U.S. patients received free AbbVie medicine<sup>1</sup>

my**AbbVie** Assist | Patient Assistance

### Health care grants seek to improve patient care quality

To better serve patients and advance medical practice and performance, we support the education of health care providers and scientists through grants. Last year, our grants helped independent scientific and medical programs deliver unbiased education on current, new and emerging science.



### Delivering award-winning patient support

In a time when many patients have delayed treatments and visits to providers due to the pandemic, our Immunology Complete programs have provided resources and support to patients at zero cost. In 2021, these programs helped more than **200,000 patients** navigate their journeys living with several immune-mediated conditions like rheumatoid arthritis and plaque psoriasis—more than double the number of patients who were enrolled in the program before the COVID-19 pandemic. Our Immunology Complete programs were recognized as one of the **Most Valuable Patient Support or Access Programs** in 2021, as part of the WEGO Health Patient-Choice Awards.

Nearly  
**700K**  
patients and  
**750K+**

health care providers supported through our independent health care grants

<sup>1</sup> Allergan Patient Assistance Program was integrated into myAbbVie Assist in 2021. This number is inclusive of the integrated program.

# Impact on science

Our innovation strives to have a positive impact on patients' lives, on society and on science itself

We approach our science with an unrelenting spirit to deliver life-changing medicines. From drug discovery to development, we're pursuing new ways to address patients' most serious health issues.



**“ We have to continue to invest in our vision, learn from failures and build on our successes. Because as long as patients are still suffering from disease, nothing’s good enough.”**

**Ahmed Kotb, M.D.**  
Vice President, U.S. Medical Affairs, Oncology, AbbVie

## Advancing scientific knowledge

**21K**

employees work in STEM

**2K+**

papers were published by our scientists in the medical research community in 2021 – allowing others to build on scientific knowledge we developed.

## Powering the future of medicine

We’re working faster and smarter to progress our pipeline and striving to deliver more personalized solutions to patients. That means expanding our capabilities across R&D to improve insights and decision-making.

**\$6.5B<sup>1</sup>**

**invested in R&D in 2021.**  
We have invested more than \$50B since the launch of AbbVie in 2013.

**90+**

compounds, devices or indications in development in our pipeline individually or under collaboration or license agreement

**2**

FDA breakthrough therapy designations in 2021

**80%**

of compounds in clinical development with novel mechanism of action<sup>2</sup>

**50+**

of these programs are in mid- and late-stage development

**250+**

partnerships with leading biotechs, universities, nonprofits and government organizations to advance science

## We tackle tough diseases and conditions:

- Acute myeloid leukemia (AML)
- Alzheimer’s disease
- Ankylosing spondylitis
- Atopic dermatitis
- Bipolar disorder
- Cancer
- Chronic migraine
- Chronic lymphocytic leukemia (CLL)
- Crohn’s disease
- Enthesitis-related arthritis
- Glaucoma
- HCV
- Hidradenitis suppurativa
- Multiple sclerosis
- Ocular hypertension
- Overactive bladder
- Parkinson’s disease
- Plaque psoriasis
- Polyarticular juvenile idiopathic arthritis
- Post-stroke spasticity
- Presbyopia
- Psoriatic arthritis
- Retinal disease
- Rheumatoid arthritis
- Schizophrenia
- Ulcerative colitis
- Uterine fibroids
- Uveitis

## Adapting clinical trials for the good of all patients

We aim to make our clinical trials more diverse, equitable and patient-centric. We do this by using new technologies to increase efficiency, broadening the diversity of study populations, accelerating recruitment and working to continually improve the patient experience.

**45K+**

patients participated in clinical trials in 2021

**70**

countries

**~8K**

study sites

## Neglected Tropical Diseases

Onchocerciasis (river blindness) is a neglected tropical disease that impacts over 17 million people. Partnering with the Drugs for Neglected Diseases Initiative, we're evaluating a potential treatment that's now in Phase 2 clinical trials. Together we've also built two clinical sites in the Democratic Republic of Congo, where roughly 80% of our clinical trial participants are enrolled.

**400+**

AbbVie scientists worked pro-bono to develop our river blindness treatment

**14K+**

research hours donated in 2021 to neglected tropical diseases, malaria and tuberculosis

<sup>1</sup> Adjusted investment in Research and Development spend is a non-GAAP measure and excludes specified items of \$0.4B compared to the as reported GAAP measure of \$6.9B.

<sup>2</sup> Indicates compounds considered "first-in-class" in the scientific community in phase III, phase II with registration potential, or in regulatory approval process. Not included are compounds considered "best-in-class", new indications, new formulations, and new forms of delivery.

# Impact on communities

We're a long-term partner in the pursuit of health and well-being

We proudly do our part, serving and supporting our communities and protecting the environment so we can make a lasting impact on health care and beyond.

## Strengthening health care systems

Our nonprofit partners are advancing health equity for communities and patients around the world through community programs that drive systems change.

### Baylor College of Medicine International Pediatric AIDS Initiative

**25K**

children and adults in Romania and Malawi received holistic HIV care, treatment, prevention and psychosocial support

### AMPATH (Academic Model Providing Access to Health Care)

**500K+**

people in Kenya screened for chronic disease and HIV, and 6K+ women in Chamas for Change groups leading to 84% of pregnant participants attending 4 antenatal visits and 94% delivering in a health facility with a skilled birth attendant

### Partners In Health

**90**

community health workers and 25 health professionals trained to improve access and care quality for patients in remote areas of Mexico

### Direct Relief\*

**\$1.8M**

in grants awarded to centers addressing health inequities in Black and marginalized communities

### University of Chicago Urban Health Initiative\*

**1,100**

patient visits facilitated by community health workers

\*In 2020, we launched a \$50 million, five-year commitment to six nonprofit partners, including these organizations, advancing health and education equity in Black and historically marginalized communities. In the year since, our partners have set the foundation for their programs and are accelerating progress. Learn more: [abbv.ie/step-by-step](https://abbv.ie/step-by-step)

## Environmental stewardship

Surpassed 2025 target of

**25%**

reduction in carbon emissions since 2015 baseline<sup>1</sup>

**92%**

of waste diverted from landfill<sup>2</sup>

**13**

projects approved through our Spark Innovation Accelerator, an incubator for employee-driven sustainability innovations

**32%**

of electricity purchased from renewable sources<sup>2</sup>

We've committed to joining the Science Based Targets initiative (SBTi). As part of this initiative, we're setting ambitious science-based, emissions reduction goals to meaningfully reduce our climate impact.

## Supporting educational programs

Our philanthropic investments advance equity in education by supporting nonprofits that address systemic barriers to advancement and empower marginalized students and young adults.

### Communities in Schools

**74K**

low-income students served in the 2020-2021 school year in 154 schools

### United Negro College Fund\*

**200**

college scholarships awarded to students pursuing health care careers

### Year Up\*

**3K**

young adults served through Year Up's job training program

### City Year

**225K**

students reached in the 2020-2021 school year at 320 schools



Photo courtesy of National Urban League

## Building strong communities

By contributing to trusted nonprofits and local programs, we're helping our communities become more resilient.

**\$1.2M**

donated to disaster relief organizations in 2021

**100**

countries have received our donated medicines since 2013

In early 2021, we expanded our support for COVID relief by enhancing access to vaccines within underserved communities.

### Nearly

**600**

AbbVie employees volunteered at vaccination clinics in Illinois

**23K+**

vaccines were administered and processed with support from AbbVie volunteers in Illinois and Puerto Rico

Launched a vaccine clinic with the Lake County Health Department, the Cities of North Chicago and Waukegan, and North Chicago Community Partners which improved vaccine access for marginalized communities by addressing transportation and technology barriers leading to vaccination of almost 6,000 seniors, many who were low-income and from a high-risk population.



**AbbVie Gives Back**  
Employee volunteering, giving and support.

Through our employee giving and matching program, we encourage charitable donations to eligible nonprofit organizations.

In 2021 nearly

**20K**

employees from

**50+**

countries raised

**\$23.7M**

for

**11,400**

nonprofits worldwide.

<sup>1</sup> Scope 1 and 2 emissions only—using a market based approach

<sup>2</sup> Excludes leased commercial offices

# Impact on jobs

We achieve breakthroughs by investing in our people and our culture

AbbVie is an economic multiplier. With approximately 50,000 employees globally, our total impact on employment is nearly five times that amount through direct and indirect business activity.\*

## Each job at AbbVie creates opportunity for others

The jobs we create attract and retain diverse talent who live, work and invest in their local communities. We treat every employee with dignity and respect and strive to ensure everyone feels that they belong and are included.

**55%**

of our global workforce are women

**51%**

of management-level employees are women

**35%**

of our U.S. workforce is from an underrepresented population

## AbbVie has a large global presence

**70+**


countries around the world where we operate

**~20**

countries where we have manufacturing and/or research and development centers

\* <https://www.phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/0-9/2020-Biopharma-Jobs-ImpactsMarch-2022-Release.pdf>

## Our 5 largest employee populations



In the United States, we have a presence in all 50 states and Puerto Rico.

Our largest employee populations by location include:

- Illinois ~10,400** (global headquarters)
- California ~3,300**
- Texas ~2,100**
- New Jersey ~1,600**
- Massachusetts ~1,300**
- Puerto Rico ~1,100**

## We create jobs & stimulate economic activity

With our investment, thousands of suppliers are met with business and growth opportunities, many of them working closely with AbbVie experts.

**51K+**

suppliers globally, across nearly 300 industries

**143**

countries with suppliers

**50**

states (plus Washington D.C. and Puerto Rico) with suppliers

**\$15.6B**

spent with third parties globally

**\$715M**

spent with approximately 1,770 small/diverse suppliers in the United States, including Puerto Rico

For more information on our impact, visit:

[abbvie.com](https://abbvie.com)

[abbv.ie/HistoryofImpact](https://abbv.ie/HistoryofImpact)



Contains 2021 data.

AbbVie Inc.

1 North Waukegan Road

North Chicago, IL 60064 U.S.A.

[abbvie.com](https://abbvie.com)

CM-0109-0622

©2022 AbbVie. All rights reserved.

ALL-ABBV-220266

**abbvie**